Business Description
Inhibrx Inc
NAICS : 325412
SIC : 2834
Description
Inhibrx Inc is a clinical-stage biotechnology company focused on developing a pipeline of novel biologic therapeutic candidates. It combines an understanding of target biology with protein engineering, proprietary discovery technologies, and an integrative approach to research and development to design differentiated therapeutic candidates. The company has four programs in clinical trials, of which three of the programs are for the treatment of various cancers, and one for the treatment of Alpha-1 Antitrypsin Deficiency.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.83 | |||||
| Equity-to-Asset | -0.21 | |||||
| Debt-to-Equity | -5.03 | |||||
| Debt-to-EBITDA | -1.58 | |||||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | -0.74 | |||||
| Beneish M-Score | -0.16 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -12.3 | |||||
| 3-Year EBITDA Growth Rate | -23.1 | |||||
| 3-Year EPS without NRI Growth Rate | -23.2 | |||||
| 3-Year FCF Growth Rate | -33.1 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 58.69 | |||||
| 9-Day RSI | 55.44 | |||||
| 14-Day RSI | 52.4 | |||||
| 6-1 Month Momentum % | 26.98 | |||||
| 12-1 Month Momentum % | -10.38 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 6.05 | |||||
| Quick Ratio | 6.05 | |||||
| Cash Ratio | 5.75 | |||||
| Days Sales Outstanding | 37.16 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -12.9 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -2384.41 | |||||
| Net Margin % | -2647.68 | |||||
| ROE % | -923.32 | |||||
| ROA % | -78.55 | |||||
| ROIC % | -721.42 | |||||
| ROC (Joel Greenblatt) % | -1263.96 | |||||
| ROCE % | -82.87 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 213.22 | |||||
| EV-to-EBIT | -10.22 | |||||
| EV-to-Forward-EBIT | -8.77 | |||||
| EV-to-EBITDA | -10.33 | |||||
| EV-to-Forward-EBITDA | -8.91 | |||||
| EV-to-Revenue | 243.43 | |||||
| EV-to-Forward-Revenue | 59.69 | |||||
| EV-to-FCF | -10.68 | |||||
| Earnings Yield (Greenblatt) % | -9.78 |
